Literature DB >> 14688067

Mouse CD20 expression and function.

Junji Uchida1, Youngkyun Lee, Minoru Hasegawa, Yinghua Liang, Alice Bradney, Julie A Oliver, Kristina Bowen, Douglas A Steeber, Karen M Haas, Jonathan C Poe, Thomas F Tedder.   

Abstract

CD20 plays a role in human B cell proliferation and is an effective target for immunotherapy. In this study, mouse CD20 expression and biochemistry were assessed for the first time using a new panel of CD20-specific mAb, with CD20 function assessed using CD20-deficient (CD20(-/-)) mice. CD20 expression was B cell restricted and was initiated during late pre-B cell development. The frequency and density of CD20 expression increased during B cell maturation in the bone marrow, with a subpopulation of transitional IgM(hi) B cells expressing higher CD20 levels than the majority of mature recirculating B cells. Transitional T1 B cells in the spleen also expressed high CD20 levels, providing a useful new marker for this B cell subset. In CD20(-/-) mice, immature and mature B cell IgM expression was approximately 20-30% lower relative to B cells from wild-type littermates. In addition, CD19-induced intracellular calcium responses were significantly reduced in CD20(-/-) B cells, with a less dramatic effect on IgM-induced responses. These results reveal a role for CD20 in transmembrane Ca(2+) movement in mouse primary B cells that complements previous results obtained using human CD20 cDNA-transfected cell lines. Otherwise, B cell development, tissue localization, signal transduction, proliferation, T cell-dependent antibody responses and affinity maturation were normal in CD20(-/-) mice. Thus, mouse and human CD20 share similar patterns of expression and function. These studies thereby provide an animal model for studying CD20 function in vivo and the molecular mechanisms that influence anti-CD20 immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688067     DOI: 10.1093/intimm/dxh009

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  83 in total

1.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 2.  Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Authors:  Peter J Bugelski; Pauline L Martin
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 4.  The MS4A family: counting past 1, 2 and 3.

Authors:  Li Eon Kuek; Melanie Leffler; Graham A Mackay; Mark D Hulett
Journal:  Immunol Cell Biol       Date:  2015-04-03       Impact factor: 5.126

5.  Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.

Authors:  Norihito Yazawa; Yasuhito Hamaguchi; Jonathan C Poe; Thomas F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

6.  B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.

Authors:  Yan Li; Gianluca Toraldo; Aimin Li; Xiaoying Yang; Hongying Zhang; Wei-Ping Qian; M Neale Weitzmann
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

Review 7.  B cell modulation in rheumatology.

Authors:  Gregg J Silverman; Sahil Khanna
Journal:  Curr Opin Pharmacol       Date:  2007-07-10       Impact factor: 5.547

Review 8.  B cells and their mediators as targets for therapy in solid tumors.

Authors:  Andrew J Gunderson; Lisa M Coussens
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

9.  CD19 expression in B cells regulates atopic dermatitis in a mouse model.

Authors:  Koichi Yanaba; Masahiro Kamata; Yoshihide Asano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2013-04-12       Impact factor: 4.307

10.  Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.

Authors:  Pu Liu; Jade Jaffar; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.